
TORONTO, Dec. 22 /CNW/ - Patheon Inc. (TSX: PTI) today announced that it has completed previously announced arrangements for new North American credit facilities in the aggregate amount of US$290 million, and has negotiated new credit facilities for its wholly owned subsidiary in Italy. "In North America, we have replaced eight different facilities in three jurisdictions with one agreement providing for two term loans and a revolving facility. This simplified structure provides Patheon with long-term, flexible and more tax-efficient funding for our North American operations," explained Robert Tedford, Chief Executive Officer, Patheon Inc. "We expect that these advantages will benefit our earnings going forward." The new North American loans replace debt facilities in Patheon's wholly owned subsidiaries in Puerto Rico assumed as part of the acquisition of MOVA Pharmaceutical Corporation in December, 2004, a one-year bridge facility provided by a group of lenders also at the time of the MOVA acquisition, and debt of its Cincinnati subsidiary. The North American facilities comprise two term loans in the aggregate amount of US$215 million and revolving facilities in the aggregate amount of US$75 million. The term loans consist of a five- year term loan in the amount of US$50 million and a six-year term loan in the amount of US$165 million, both of which can be repaid at any time without penalty. The new facilities are secured by the North American assets of Patheon and its subsidiaries, including those in Puerto Rico. Royal Bank of Canada and RBC Capital Markets, as Lead Arranger, syndicated these new credit facilities to a group of financial institutions in Canada and the United States and Puerto Rico. Patheon's wholly owned Italian subsidiary also entered into a new debt facility today. The new loan replaced four separate term loans it had with an Italian bank with a new credit facility with the same bank. The new loan aggregating 28.5 million euros matures in 2014 and has equal semi-annual principal payments over the term of the nine-year loan. The new facility will be secured by the assets of Patheon's Italian operations, and a parent guarantee from Patheon Inc. in the amount of 15 million euros, which is a 10 million euro reduction from the level of parent company guarantees that Patheon Inc. had provided under the prior facilities. "These new credit facilities improve our debt arrangements and provide stable debt financing for the next five years in North America and nine years in Italy," concluded Mr. Tedford. Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 180 pharmaceutical and biotechnology companies. This news release contains forward-looking statements with respect to Patheon, including its business operations and strategy and financial performance and condition. Although management believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from expectations include, but are not limited to, currency fluctuations, the level of outsourcing services required by the pharmaceutical companies (and in particular our clients), the impact of changes in pharmaceutical development and manufacturing regulations and general economic and market factors (including inflation and changes in laws) and other factors discussed in materials filed with applicable securities regulatory authorities from time to time. %SEDAR: 00001700E